The estimated Net Worth of Lisa Anne Michaels is at least $343 mil dollars as of 12 November 2021. Dr Michaels owns over 1,568 units of Editas Medicine Inc stock worth over $69,673 and over the last 4 years he sold EDIT stock worth over $60,101. In addition, he makes $213,467 as Exec. VP & Chief Medical Officer at Editas Medicine Inc.
Dr has made over 1 trades of the Editas Medicine Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 1,568 units of EDIT stock worth $60,101 on 12 November 2021.
The largest trade he's ever made was selling 1,568 units of Editas Medicine Inc stock on 12 November 2021 worth over $60,101. On average, Dr trades about 523 units every 0 days since 2020. As of 12 November 2021 he still owns at least 18,432 units of Editas Medicine Inc stock.
You can see the complete history of Dr Michaels stock trades at the bottom of the page.
Dr. Lisa A. Michaels M.D. is the Exec. VP & Chief Medical Officer at Editas Medicine Inc.
As the Exec. VP & Chief Medical Officer of Editas Medicine Inc, the total compensation of Dr D at Editas Medicine Inc is $213,467. There are 8 executives at Editas Medicine Inc getting paid more, with Cynthia Collins having the highest compensation of $14,489,700.
Dr D is 55, he's been the Exec. VP & Chief Medical Officer of Editas Medicine Inc since . There are 13 older and 4 younger executives at Editas Medicine Inc. The oldest executive at Editas Medicine Inc is Dr. George McDonald Church Ph.D., 67, who is the Co-Founder & Scientific Advisory Board Member.
Lisa's mailing address filed with the SEC is C/O EDITAS MEDICINE, INC., 11 HURLEY ST., CAMBRIDGE, MA, 02141.
Over the last 9 years, insiders at Editas Medicine Inc have traded over $73,429,036 worth of Editas Medicine Inc stock and bought 241,700 units worth $4,697,822 . The most active insiders traders include Andrew A. F. Hack, Kevin P Starr, eKevin Bitterman. On average, Editas Medicine Inc executives and independent directors trade stock every 22 days with the average trade being worth of $126,770. The most recent stock trade was executed by Baisong Mei on 4 September 2024, trading 518 units of EDIT stock currently worth $1,772.
unlocking the promise of genome editing to deliver life-changing medicines. editas medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.
Editas Medicine Inc executives and other stock owners filed with the SEC include: